Metabolic Health: 5 Markers, 88% Failure Rate, and How CGMs Reveal What Blood Tests Miss
Only 12.2% of American adults are metabolically healthy. This guide explains the 5 diagnostic markers, why most people fail them, how insulin resistance quietly drives metabolic decline, and how continuous glucose monitors detect dysfunction years before standard lab work.
What Is Metabolic Health?
Metabolic health is the state in which all 5 cardiometabolic markers fall within optimal ranges without the assistance of medication. Those 5 markers are fasting blood glucose, blood pressure, triglycerides, HDL cholesterol, and waist circumference. When all 5 are in range, the body efficiently converts food into energy, maintains stable blood sugar, clears lipids from the bloodstream, and regulates inflammation — the core functions that protect against heart disease, type 2 diabetes, stroke, and certain cancers.
A landmark 2018 study from the University of North Carolina at Chapel Hill, led by Joana Araújo and published in Metabolic Syndrome and Related Disorders, analyzed NHANES data from 8,721 adults and found that only 12.2% of American adults meet all 5 metabolic health criteria. That means 87.8% — roughly 228 million people — have at least 1 marker outside optimal range. The study further showed that metabolic health declined with age: 25% of adults aged 20-39 were metabolically healthy, compared to just 2% of adults over 60. Even among people with a normal body mass index (BMI 18.5-24.9), only 32.8% were metabolically healthy, demonstrating that weight alone is a poor proxy for metabolic status.
Metabolic health, as defined in clinical research, refers specifically to the absence of metabolic syndrome criteria plus the absence of medication use for any of the 5 markers. This is a stricter definition than simply having “normal” lab results, because a person whose blood pressure is controlled by lisinopril or whose glucose is managed by metformin does not qualify as metabolically healthy under this framework — their underlying dysfunction persists, just chemically masked.
The 5 Metabolic Health Markers Explained
Five measurements define whether the body's energy metabolism, cardiovascular regulation, and fat storage systems are functioning within safe parameters. Each marker has 3 clinical zones: optimal, borderline (elevated risk), and unhealthy (diagnostic threshold for metabolic syndrome). Failing 3 or more markers constitutes a formal diagnosis of metabolic syndrome.
| Marker | Optimal | Borderline | Unhealthy (MetS Cutoff) |
|---|---|---|---|
| Fasting Blood Glucose | < 100 mg/dL | 100 – 109 mg/dL | ≥ 110 mg/dL |
| Blood Pressure | < 120/80 mmHg | 120-129 / < 80 mmHg | ≥ 130/85 mmHg |
| Triglycerides | < 150 mg/dL | 150 – 199 mg/dL | ≥ 150 mg/dL |
| HDL Cholesterol | ≥ 60 mg/dL | 40–59 mg/dL (men) / 50–59 (women) | < 40 mg/dL (men) / < 50 (women) |
| Waist Circumference | < 35" (men) / < 30" (women) | 35–39" (men) / 30–34" (women) | ≥ 40" (men) / ≥ 35" (women) |
Source: National Heart, Lung, and Blood Institute (NHLBI) and Adult Treatment Panel III (ATP III) criteria. The International Diabetes Federation (IDF) uses lower waist circumference cutoffs for non-European populations.
Why Metabolic Health Matters: Disease Risk by the Numbers
Metabolic dysfunction is the single strongest modifiable predictor of cardiovascular disease, type 2 diabetes, and all-cause mortality. The Framingham Heart Study — a 75-year longitudinal study tracking 3 generations of participants in Framingham, Massachusetts — established that individuals with metabolic syndrome have a 2x higher risk of cardiovascular events (heart attack, stroke, heart failure) and a 5x higher risk of developing type 2 diabetes within 10 years compared to metabolically healthy individuals.
The risk extends beyond heart disease and diabetes. A 2020 meta-analysis published in The Lancet Diabetes & Endocrinology analyzing 133 prospective studies (N = 12.8 million participants) found that metabolic syndrome increased the risk of colorectal cancer by 33%, endometrial cancer by 61%, and liver cancer by 43%. Insulin resistance — the hormonal engine behind metabolic syndrome — promotes tumor growth by elevating circulating insulin and insulin-like growth factor 1 (IGF-1), both of which stimulate cell proliferation and inhibit apoptosis (programmed cell death).
Cognitive decline is also directly linked to metabolic health. The Whitehall II study, which followed 10,308 British civil servants for 25 years, found that participants with metabolic syndrome at midlife experienced a 13.4% faster decline in cognitive function over the following 2 decades. Elevated fasting glucose alone — even in the “normal” range above 90 mg/dL — was associated with reduced hippocampal volume on brain MRI, according to a 2013 study in Neurology by Cherbuin et al.
All-cause mortality follows a clear gradient. A 2017 analysis of 942,366 participants across 73 studies, published in the Journal of the American College of Cardiology, found that individuals with 4 or 5 metabolic syndrome components had a 59% higher all-cause mortality rate compared to those with zero components. Each additional failed marker increased 10-year mortality risk by approximately 10-15%.
Insulin Resistance: The Root Cause Behind 4 of 5 Markers
Insulin resistance is the condition in which muscle, fat, and liver cells fail to respond normally to the hormone insulin, forcing the pancreas to produce progressively larger amounts to maintain blood glucose control. It is the underlying metabolic defect behind 4 of the 5 metabolic health markers — fasting glucose, triglycerides, HDL cholesterol, and blood pressure all deteriorate as insulin resistance worsens. An estimated 40% of U.S. adults aged 18-44 have some degree of insulin resistance according to a 2022 analysis in JAMA Network Open.
The progression follows a predictable 10-to-15-year timeline. In the earliest stage, cells begin to resist insulin's signal to absorb glucose. The pancreas compensates by producing 2x to 5x more insulin than normal — a condition called hyperinsulinemia. During this stage, fasting glucose and A1C remain normal because the extra insulin is successfully forcing glucose into cells. Standard blood tests show nothing abnormal. Only fasting insulin levels (above 12 μIU/mL) or HOMA-IR calculations reveal the problem.
As insulin resistance progresses over years, the pancreas can no longer keep up with demand. Fasting glucose rises above 100 mg/dL (prediabetes threshold), A1C climbs above 5.7%, and postmeal glucose spikes become larger and longer. This is the prediabetic stage, affecting 96 million American adults (38% of the adult population) according to CDC 2022 data. Without intervention, 15-30% of people with prediabetes progress to type 2 diabetes within 5 years.
The key insight for CGM users is that insulin resistance is detectable through glucose patterns long before standard lab markers become abnormal. A metabolically healthy person returns to baseline glucose within 60-90 minutes after a meal. A person with early insulin resistance shows postmeal glucose elevations lasting 2-3 hours and higher peak values. This is why continuous glucose monitoring is the most sensitive non-invasive screening tool for early metabolic dysfunction — it reveals the dynamic response to food, exercise, and stress that static fasting blood tests cannot capture. The best CGMs for metabolic health tracking achieve MARD accuracy of 7.9-9.1% and provide the 5-minute data resolution needed to detect these early patterns. For a deeper exploration, see the full insulin resistance guide.
How CGMs Reveal Metabolic Dysfunction Before Standard Tests
A continuous glucose monitor captures 288 glucose readings per day, exposing metabolic patterns that a single fasting blood draw cannot detect. Standard metabolic screening relies on a fasting glucose measurement (one number from one moment) and A1C (a 2-3 month average that masks daily variability). A CGM, by contrast, generates a complete time-series dataset showing exactly how the body responds to every meal, workout, stressful event, and night of sleep.
Three CGM-derived metrics serve as early warning signals for metabolic dysfunction. First, postprandial glucose peaks above 140 mg/dL indicate impaired glucose tolerance even when fasting glucose is normal. A 2018 study in PLOS Biologyby Hall et al. at Stanford University found that 80% of participants classified as “normal” by standard criteria exhibited glucose spikes exceeding 140 mg/dL after high-carbohydrate meals — levels that damage endothelial cells lining blood vessels and accelerate atherosclerosis.
Second, glucose variability measured by coefficient of variation (CV) is emerging as an independent risk marker. A CV above 36% — meaning glucose swings widely throughout the day — correlates with increased oxidative stress, inflammation, and cardiovascular risk independent of average glucose. The 2019 International Consensus on Time in Range identified CV as a key metric that should be reported alongside Time in Range.
Third, time to return to baseline after meals is a practical CGM metric for assessing insulin function. A healthy metabolic response returns glucose to within 10 mg/dL of the pre-meal value within 90 minutes. Individuals with early insulin resistance typically require 120-180 minutes, and those with prediabetes may not fully return to baseline before the next meal. Tracking this metric over weeks with a CGM provides a functional assessment of insulin sensitivity that no blood test can replicate.
Metabolic Syndrome: When 3 or More Markers Fail
Metabolic syndrome is the clinical diagnosis assigned when a person meets 3 or more of the 5 cardiometabolic criteria simultaneously. It affects approximately 35% of American adults — roughly 84 million people — according to NHANES data from the National Heart, Lung, and Blood Institute. Metabolic syndrome is not a disease itself but a cluster of risk factors that dramatically increases the likelihood of cardiovascular events and type 2 diabetes.
Two competing diagnostic frameworks exist. The Adult Treatment Panel III (ATP III) criteria, established by the NHLBI in 2001 and updated in 2005, require 3 of 5 markers with equal weighting — no single marker is mandatory. The International Diabetes Federation (IDF)criteria, introduced in 2005, require central obesity (elevated waist circumference) as a mandatory prerequisite plus 2 of the remaining 4 markers. The IDF also uses ethnicity-specific waist circumference thresholds: ≥94 cm for European men, ≥80 cm for European women, and ≥90 cm for South Asian and Chinese men. In clinical practice, most U.S. physicians use the ATP III criteria.
The cardiovascular risk amplification is substantial. Having metabolic syndrome doubles the 10-year risk of a cardiovascular event and increases the risk of type 2 diabetes 5-fold compared to individuals without the syndrome. A 2016 meta-analysis in the Journal of the American Heart Association found that metabolic syndrome increased stroke risk by 46%, coronary heart disease by 99%, and cardiovascular mortality by 68%. Importantly, the risk from metabolic syndrome exceeds the sum of its individual components — the combination of markers produces a synergistic effect on vascular damage. For the full diagnostic criteria, treatment options, and risk stratification, see the metabolic syndrome guide.
Testing Your Metabolic Health: 7 Lab Values to Request
A standard metabolic panel ordered during an annual physical misses the earliest and most actionable markers of metabolic dysfunction. Most physicians order a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP), which includes fasting glucose but omits fasting insulin, A1C, and inflammatory markers. To get a complete picture, you need to specifically request the following tests.
Fasting Insulin
The earliest metabolic marker. Fasting insulin rises 10-15 years before fasting glucose becomes abnormal. Optimal: below 8 μIU/mL. Concerning: above 12 μIU/mL. Insulin resistant: above 20 μIU/mL. This test costs $25-$50 at most labs but is not included in standard panels — you must request it. See the full fasting insulin guide.
HOMA-IR
Calculated from fasting insulin and fasting glucose.Formula: (fasting insulin × fasting glucose) ÷ 405. A HOMA-IR below 1.0 indicates excellent insulin sensitivity. Above 1.9 suggests early insulin resistance. Above 2.9 indicates significant insulin resistance. This is the gold standard screening calculation for insulin resistance in clinical research.
A1C (Glycated Hemoglobin)
Reflects average blood glucose over 2-3 months. Normal: below 5.7%. Prediabetes: 5.7-6.4%. Diabetes: 6.5% or higher. While useful for trending, A1C has known limitations — hemoglobin variants (common in African American, Southeast Asian, and Mediterranean populations) can falsely elevate or depress A1C readings by up to 1.0%. See the A1C test guide.
Lipid Panel (Triglycerides + HDL)
The triglyceride-to-HDL ratio is a powerful insulin resistance proxy. A ratio above 3.0 in Caucasian populations or above 2.0 in African American populations strongly predicts insulin resistance. Optimal triglycerides: below 100 mg/dL. Optimal HDL: above 60 mg/dL. The lipid panel is included in most annual physicals but the ratio is rarely calculated or flagged by physicians.
hs-CRP (High-Sensitivity C-Reactive Protein)
Measures systemic inflammation, a key driver and consequence of metabolic dysfunction. Low risk: below 1.0 mg/L. Moderate risk: 1.0-3.0 mg/L. High risk: above 3.0 mg/L. The JUPITER trial demonstrated that elevated hs-CRP independently predicts cardiovascular events even when LDL cholesterol is normal. See the inflammation and blood sugar guide.
Fasting Glucose
Standard but late-stage marker.Fasting glucose only becomes abnormal (above 100 mg/dL) after years of insulin resistance have exhausted the pancreas's compensatory capacity. Optimal: 72-85 mg/dL. Normal: below 100 mg/dL. Prediabetes: 100-125 mg/dL. Diabetes: 126 mg/dL or above on 2 separate tests.
ALT (Alanine Aminotransferase)
Screens for non-alcoholic fatty liver disease (NAFLD), present in 80% of people with metabolic syndrome. Normal: below 25 U/L for women, below 33 U/L for men. Elevated ALT in the context of metabolic syndrome suggests hepatic fat accumulation, which independently worsens insulin resistance. The complete lab test guide covers all 12 recommended metabolic markers in the metabolic health tests page.
How to Improve Metabolic Health: 5 Evidence-Based Starting Points
Metabolic health is modifiable — the majority of people with metabolic syndrome or insulin resistance can improve or fully normalize their markers through lifestyle changes within 3-6 months. The Diabetes Prevention Program (DPP), a landmark NIH-funded trial of 3,234 participants, proved that lifestyle intervention (150 minutes of weekly exercise plus 5-7% weight loss) reduced the progression from prediabetes to type 2 diabetes by 58% — outperforming metformin medication (31% reduction) by nearly 2 to 1.
1. Exercise 150 Minutes per Week
A 2022 Diabetes Care meta-analysis found that 8 weeks of moderate aerobic exercise improved insulin sensitivity by 30% as measured by the euglycemic clamp method. Walking 30 minutes daily 5 days per week meets this threshold. Adding 2 sessions of resistance training per week increases GLUT4 glucose transporter expression in muscle cells by up to 40%, further improving glucose uptake.
2. Reduce Refined Carbohydrates
Replacing refined grains and added sugars with vegetables, legumes, and whole grains reduces postmeal glucose spikes by 25-40% as measured by CGM. A 2021 randomized trial in BMJ found that a lower-glycemic diet reduced A1C by 0.3% and fasting insulin by 17% over 12 weeks without calorie restriction.
3. Sleep 7-9 Hours Consistently
Spiegel et al. demonstrated in a 1999 Lancet study that restricting sleep to 4 hours for just 6 nights reduced insulin sensitivity by 40% and increased cortisol levels by 37%. A 2023 Annals of Internal Medicine trial showed that extending sleep from 6.5 to 8.5 hours for 2 weeks reduced caloric intake by 270 calories per day and improved fasting glucose.
4. Lose 5-7% of Body Weight
The DPP trial's most powerful finding: a modest 5-7% weight loss (10-14 pounds for a 200-pound person) produced the 58% reduction in diabetes risk. Weight loss reduces visceral fat — the metabolically active fat surrounding organs that secretes inflammatory cytokines and drives insulin resistance. Even without exercise changes, caloric reduction sufficient for this weight loss improves all 5 metabolic markers.
5. Use CGM-Guided Optimization
A continuous glucose monitor provides real-time feedback on which foods, activities, and behaviors improve or worsen your metabolic response. Instead of following generic dietary advice, CGM data reveals your individual glycemic response — which varies significantly between people due to differences in gut microbiome, genetics, and insulin sensitivity. A 2020 randomized trial in Nature Medicine demonstrated that CGM-guided personalized nutrition reduced postmeal glucose spikes by 32% compared to standard dietary counseling. Over-the-counter CGMs cost $49 to $99 per month without a prescription, making metabolic health tracking financially accessible. For a complete evidence-based improvement protocol, see the 8 strategies to improve metabolic health.
Deep Dives: Metabolic Health Topics
Insulin Resistance Explained: Causes, 14 Symptoms, and Reversal Strategies
Read guide →
Metabolic Syndrome: 5 Diagnostic Criteria and Cardiovascular Risk Factors
Read guide →
A1C Test Explained: Ranges, Accuracy Limitations, and CGM Correlation
Read guide →
Fasting Insulin and HOMA-IR: Advanced Metabolic Markers Your Doctor May Skip
Read guide →
Inflammation and Blood Sugar: How CRP and Glucose Interact
Read guide →
Hormones and Blood Sugar: Cortisol, Thyroid, Estrogen, and Testosterone Effects
Read guide →
Metabolic Health Tests: 12 Lab Values Your Doctor Should Order
Read guide →
How to Improve Metabolic Health: 8 Evidence-Based Strategies That Work
Read guide →
When Metabolic Health Is Optimal
The 12.2% of American adults who meet all 5 metabolic health criteria exhibit a distinct CGM signature: fasting glucose between 72 and 85 mg/dL, postmeal spikes that rarely exceed 120 mg/dL, and a return to baseline within 60 to 90 minutes after eating. For these metabolically healthy individuals, a CGM confirms that their diet, exercise, and sleep habits are producing optimal results — and provides early warning if any metric begins to drift. To explore how non-diabetic users leverage CGM data for weight loss, athletic performance, and longevity optimization, see the CGM for wellness guide.
Related Resources
- Best CGMs for Metabolic Health in 2026 — Data-driven rankings of every continuous glucose monitor by accuracy, sensor wear time, and monthly cost.
- CGM Cost Guide: Pricing and Insurance — OTC options from $49, prescription devices, Medicare coverage, and FSA/HSA eligibility.
- CGM Services with Metabolic Health Coaching — Nutrisense, Levels, Signos, and Veri — dietitian coaching, insulin resistance tracking, and pricing.
- Conditions and CGM Use Cases — How continuous glucose monitors are used for type 1 diabetes, type 2 diabetes, prediabetes, gestational diabetes, and non-diabetic wellness.
- Blood Sugar Basics — Normal glucose ranges, postmeal targets, hypoglycemia and hyperglycemia thresholds, and how glucose regulation works.
- CGM and Nutrition — How food affects glucose, glycemic index vs glycemic load, meal timing, macronutrient composition, and CGM-guided dietary strategies.
- Wellness and Non-Diabetic CGM Use — Over-the-counter CGMs, metabolic optimization, athletic performance tracking, and biohacking applications.
- Metabolic and Glucose Monitoring Terminology — Definitions for insulin resistance, A1C, HOMA-IR, metabolic syndrome, and 50+ other terms used in glucose monitoring.